Minerva Neurosciences Announces Departure of Directors
(Thomson Reuters ONE) -
WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the
development of therapies to treat central nervous system disorders, today
announced the resignation of two members of its board of directors, Michele
Ollier and Nico Vandervelpen. Following the Company's recent public offering
and the resultant improvement in its financial position, Dr. Ollier and Mr.
Vandervelpen will step down to focus on their private equity activities. Their
resignations are effective today.
"We would like to thank Michele and Nico for their invaluable contributions to
Minerva as a private company and as it has transitioned during the past three
years from a venture capital-backed company to a publicly traded company that
has advanced several assets into late-stage clinical development," said Marc
Beer, chairman of Minerva.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in
clinical development for schizophrenia; MIN-202 (JNJ-42847922), in clinical
development for insomnia and major depressive disorder (MDD); MIN-117, in
clinical development for MDD; and MIN-301, in pre-clinical development for
Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global
Market under the symbol "NERV." For more information, please
visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via GlobeNewswire
Datum: 24.07.2017 - 14:30 Uhr
Sprache: Deutsch
News-ID 553574
Anzahl Zeichen: 2319
contact information:
Town:
Waltham
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Minerva Neurosciences Announces Departure of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Minerva Neurosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
